A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis

Myelofibrosis (MF) is a progressive disease characterized by accumulation of extracellular matrix (ECM) in the bone marrow (BM) which impairs normal hematopoiesis. While Janus kinase (JAK) inhibitors reduce spleen volume and provide symptomatic improvement, they do not resolve BM fibrosis and may c...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Pankit Vachhani, Peter Tan, Anne-Marie Watson, Shang-Ju Wu, Ross Baker, Stanley Cheung, Sung-Eun Lee, Chih-Cheng Chen, Tsai-Yun Chen, Hui-Hua Hsiao, Jae Hoon Lee, Lucia Masarova, Shuh Ying Tan, Jana Baskar, Brett Charlton, Alison Findlay, Dieter Hamprecht, Wolfgang Jarolimek, Joanna Leadbetter, John Miller, Kristen Morgan, Amna Zahoor, Gabriela Hobbs
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-04-01
Online Access:	https://haematologica.org/article/view/12032